{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/olecranon-bursitis/management/management/","result":{"pageContext":{"chapter":{"id":"8eafa19f-9b61-5217-a60d-8b7150c8d22e","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 7d4127f6-2784-473d-a32a-2b5eead402eb --><h2>Scenario: Management</h2><!-- end field 7d4127f6-2784-473d-a32a-2b5eead402eb -->","summary":"Covers the management and referral of both non-septic and septic olecranon bursitis.","htmlStringContent":"<!-- begin item 72f1fabe-371a-4651-a909-324912c01440 --><!-- begin field 7cc382c4-2068-4dcb-974e-acbc015a5d0a --><p>From age 16 years onwards.</p><!-- end field 7cc382c4-2068-4dcb-974e-acbc015a5d0a --><!-- end item 72f1fabe-371a-4651-a909-324912c01440 -->","topic":{"id":"677058a2-327c-5c74-b020-fa294dc001d6","topicId":"2b5681b1-a6ac-486f-9c29-562f1d00c942","topicName":"Olecranon bursitis","slug":"olecranon-bursitis","lastRevised":"Last revised in January 2021","chapters":[{"id":"a4276506-6266-5cf4-a65d-b517b5e29073","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5f6379bf-0c3e-5f36-b626-ae14f093855a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"30dc5fe8-8e10-5195-be9c-2032a2fe9c29","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"606247ee-02bd-5fbb-ac4e-00181cb9d573","slug":"changes","fullItemName":"Changes"},{"id":"13cfdc08-b4d8-56a4-a5ac-0dfa1d7e6cfe","slug":"update","fullItemName":"Update"}]},{"id":"3f962ec9-103d-50a6-876c-4a47fb7de1c6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c7da3eeb-0643-5b34-ab2c-8ba9d3db1032","slug":"goals","fullItemName":"Goals"},{"id":"ce4821e2-3cc9-5e64-a68c-2347bb4c8b71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d54ee925-bde2-5a23-a8d7-5890790b3298","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55611326-78d9-5af9-a3d8-3243f894aff6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"97a3cb4a-8ad1-5279-9a00-d3071c8afd3f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ae95433-ad22-5338-aab8-270312eb6fa0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9d59d92b-a3ce-5a17-ad08-8bdcd5032439","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"198864d0-53c2-5b2c-b236-08be4dd0177d","slug":"definition","fullItemName":"Definition"},{"id":"1c159260-37b3-563a-831f-16da306c92e0","slug":"causes","fullItemName":"Causes"},{"id":"83714e1b-4423-54d1-893d-80c2a92a842a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e2b0682f-f14b-5991-9d25-9d0a5572ae36","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a6ff79ed-b8bd-5dde-b777-048ebe2f83e8","slug":"complications","fullItemName":"Complications"}]},{"id":"f4ab30bf-b462-5a3f-bf5c-a27ae9d3e6ff","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1d3747f8-bed3-50aa-9617-789459b5adf6","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"7ad7f12d-d8f0-59d8-8841-9ecbe656356c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"653f7410-1fe1-5ae6-a30f-00e9b38f6285","slug":"aspiration","fullItemName":"Aspiration"}]},{"id":"33abb1c3-d06d-580c-8e89-c9f79202fcdd","fullItemName":"Management","slug":"management","subChapters":[{"id":"8eafa19f-9b61-5217-a60d-8b7150c8d22e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4cc6cfee-67bb-5942-a9b4-d95ff1d2b51a","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0c0460df-e8f1-55c6-9812-ab8d4105711c","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"fa9d8342-ae93-5e02-bc7e-bc3667cbfbc9","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cdb27da7-1335-559d-9d4b-3fc3a0b6bc9b","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"004b3dea-95a9-59e3-8f0e-2c801e5ebb1a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06e783b5-d47f-55ea-b7be-a3cbd73f4ddb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1fb7925d-db93-5872-9164-840da5cf1d91","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6a47a3d4-5551-565a-a0f6-618797e318a7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8a12dab5-123e-505b-bb29-69626a4ef54e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3600086-ecd1-5ccd-9711-0f1444616612","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87436259-d98d-5e39-ba2d-28c6133751e5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5c35d7b1-2c5b-5fd5-9de1-d0a85c2d7931","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"33abb1c3-d06d-580c-8e89-c9f79202fcdd","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"beb60fb1-dac0-59b7-8168-81f7eba62890","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 040e6f1e-6f46-454e-b6b2-8530e2e88d69 --><h3>How should I manage olecranon bursitis?</h3><!-- end field 040e6f1e-6f46-454e-b6b2-8530e2e88d69 -->","summary":null,"htmlStringContent":"<!-- begin item 9cf4231f-5e88-4260-b24d-724bbbbebe58 --><!-- begin field 3b5e750d-c02d-4b90-8e36-c45a89139fb9 --><ul><li><strong>Advise the person to use conservative measures until symptoms improve. These include:</strong><ul><li>Rest, ice, and reduced activity. Avoiding trauma or direct pressure to the elbows and/or the use of protective elbow pads is recommended. <ul><li>Ice may be used to reduce swelling. It can be applied topically to the area for 10 minutes at a time, every few hours (but not directly onto the skin; a thin towel can be placed between ice and skin). </li></ul></li><li>Compressive bandaging (for example an elasticated tubular bandage such as Tubigrip<sup>®</sup>, Comfigrip<sup>®</sup>, EasiGRIP<sup>®</sup>, Eesiban<sup>®</sup>) if tolerated.</li><li>Considering the use of an analgesic for pain relief — paracetamol or a nonsteroidal anti-inflammatory drug (NSAID), such as ibuprofen. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</li></ul></li><li><strong>If clinically confident that the bursitis is non-septic:</strong><ul><li>Reassure the person that most people will respond to conservative treatment.</li><li>Advise the person to re-attend if there are worsening symptoms, such as increasing pain and spreading inflammation, which could be caused by infection.</li><li>Consider <a class=\"topic-reference internal-reference\" href=\"/topics/olecranon-bursitis/diagnosis/aspiration/\">aspiration</a> (if the expertise and equipment are available) to improve function and comfort, particularly if the effusion is large.</li><li>If there is no response to conservative measures and/or aspiration, consider a corticosteroid injection into the bursa only if you are confident that bursitis is non-septic and there is expertise and experience at performing this procedure.<ul><li>If the requisite skills are not available and/or there is a risk of introducing or aggravating infection (signs of inflammation, a surgical scar, or abnormal skin at the injection site), refer to a specialist.</li></ul></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/olecranon-bursitis/management/management/#admission-or-referral\">Refer</a> if there is no response to available treatments in primary care after 2 months.</li></ul></li><li><strong>If septic bursitis is suspected:</strong><ul><li>Aspirate<strong> </strong>bursal fluid using an aseptic technique<strong> </strong>and treat empirically with an oral antibiotic which covers staphylococcal and streptococcal species until culture results are known. If aspiration is not possible, treat empirically with an oral antibiotic and refer for aspiration.<ul><li>Flucloxacillin (500 mg four times a day) is the preferred antibiotic.</li><li>Clarithromycin (500 mg twice a day) may be used if the person is allergic to penicillin. Erythromycin (500 mg four times a day) is the preferred macrolide in pregnancy and breastfeeding.</li><li>If the person is immunocompromised, seek specialist advice.</li></ul></li><li> Review after 7 days or sooner if there are worsening symptoms. If there is some response, but the infection has not completely resolved, continue antibiotics for another 7 days.</li><li>Adjust antibiotic treatment according to sensitivities.</li><li>If swelling, tenderness, and erythema recur, consider repeated <a class=\"topic-reference internal-reference\" href=\"/topics/olecranon-bursitis/diagnosis/aspiration/\">aspiration</a>. The period between aspirations should be guided by clinical response.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/olecranon-bursitis/management/management/#admission-or-referral\">Admit or refer</a> (depending on severity of symptoms) if the response is inadequate or complications are suspected.</li></ul></li><li>If the person has gout, rheumatoid arthritis, or associated cellulitis, ensure that these conditions are managed appropriately. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/gout/\">Gout</a>, <a class=\"topic-reference external-reference\" href=\"/topics/rheumatoid-arthritis/\">Rheumatoid arthritis,</a> and <a class=\"topic-reference external-reference\" href=\"/topics/cellulitis-acute/\">Cellulitis - acute</a>.</li></ul><!-- end field 3b5e750d-c02d-4b90-8e36-c45a89139fb9 --><!-- end item 9cf4231f-5e88-4260-b24d-724bbbbebe58 -->","subChapters":[{"id":"3aa1785b-789d-5fc4-9e2b-a5f08f328169","slug":"basis-for-recommendation-dd5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2a0e9716-0469-43d2-91a4-bbd874eea4ae --><h4>Basis for recommendation</h4><!-- end field 2a0e9716-0469-43d2-91a4-bbd874eea4ae -->","summary":null,"htmlStringContent":"<!-- begin item dd5fd99e-79ac-4ae0-be1b-6eca34c9078c --><!-- begin field 9a932cb9-1ea7-4fb4-b6f0-54a9b2a0a101 --><p>The recommendations on the management of olecranon bursitis in primary care are based on expert opinion in a consensus guideline on elbow disorders from the American College of Occupational and Environmental Medicine (ACOEM) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Hegmann, 2013</a>]; a systematic review of current treatments for olecranon bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Baumbach et al, 2014</a>], expert opinion in a chapter from a textbook on olecranon bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Cassidy and Shubert, 2014</a>], expert opinion in review articles on the management of olecranon bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">McFarland et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Degreef and De Smet, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Del Buono et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Smith, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Reilly and Kamineni, 2016</a>], and the British Medical Journal (BMJ) Best practice review on the diagnosis and management of bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>].</p><h5>Conservative measures</h5><ul><li>One systematic review of literature on the treatment of olecranon bursitis (which identified 52 relevant papers) concluded that non-septic olecranon bursitis usually responds well to conservative treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Hegmann, 2013</a>]. In addition, expert opinion in review articles recommends that conservative measures, including avoidance of direct trauma to the olecranon and the use of soft padding on the elbow should be used for both non-septic bursitis and septic bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Smith, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>].</li><li>The information on the use of ice is based on the British Medical Journal Best practice review article on bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>].</li><li>Evidence for the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of olecranon bursitis is not conclusive and there is no consensus from expert opinion regarding the use of NSAIDs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Hegmann, 2013</a>]. However, some expert opinion in review articles advocates their use as they provide analgesic and anti-inflammatory relief, and may allow an earlier range of motion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Stell, 1996</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Cassidy and Shubert, 2014</a>].</li><li>CKS found no evidence on the use of paracetamol for olecranon bursitis, and this advice is based on established clinical practice for simple analgesia.</li></ul><h5>Non-septic olecranon bursitis</h5><ul><li>Routine aspiration for non-septic bursitis has been advocated by some experts as an appropriate treatment to shorten the natural history of the condition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Degreef and De Smet, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>]. However, other experts in review articles on the management of non-septic olecranon bursitis oppose this based on the increased risk of infection with this treatment approach [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>]. <ul><li>One randomized trial (n = 133) compared compression bandaging plus NSAIDs, aspiration, and aspiration plus corticosteroid injections for the treatment of non-septic olecranon bursitis, and found no difference between treatments in terms of symptom resolution at 4 weeks. The authors concluded that because olecranon bursitis can recur, and treatments like aspiration and aspiration plus corticosteroid injection may lead to complications, compression bandaging with a short course of NSAIDs may offer the most appropriate balance of safety and efficacy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Kim et al, 2016</a>].</li><li>If the bursa is much enlarged then aspiration may be considered more appropriate to improve function and comfort [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Cassidy and Shubert, 2014</a>].</li></ul></li></ul><h5>Corticosteroid injections</h5><ul><li>Corticosteroid injections are not routinely recommended in primary care for the treatment of non-septic or septic olecranon bursitis because of the difficulty in differentiating between the conditions, the risks of exacerbating infection, and concerns about adverse effects such as skin atrophy.</li><li>Corticosteroid injection is suggested by some experts for the treatment of recurrent bursitis, but only after conservative treatment has been tried, and it should not be done if infection is suspected [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Cardone and Tallia, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Kim et al, 2016</a>]. Corticosteroid injections are not recommended in septic bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>].</li><li>Previous expert reviewers of this CKS topic suggest that long-term complications of corticosteroid injections for olecranon bursitis are unlikely, and that corticosteroid injections may be used in primary care provided that septic bursitis has been excluded by aspirate Gram staining and culture. CKS considers it to be good clinical practice that this procedure is only performed by someone with the relevant expertise and experience.</li></ul><h5>Antibiotic treatment for septic bursitis</h5><ul><li>Uncomplicated superficial septic bursitis responds well to needle aspiration of the bursa and appropriate antibiotic therapy. In most cases of septic olecranon bursitis, the infecting organism is <em>Staphylococcus aureus</em> and initial antimicrobial therapy should cover staphylococci and streptococci until the culture result is known. Most people respond well to a penicillinase-resistant penicillin or a macrolide (such as clarithromycin or erythromycin) as an oral alternative for penicillin-allergic patients [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>].<ul><li>Flucloxacillin is recommended as first-line because it is active against most susceptible Gram-positive cocci, including beta-lactamase-producing staphylococci and streptococci. It penetrates well into most tissues, and is suitable for skin and soft tissue infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Finch et al, 2010</a>].</li><li>Macrolides have a broad spectrum of activity and are active against most sensitive Gram-positive cocci (including staphylococci and streptococci), and some Gram-negative cocci and anaerobes. Clarithromycin may be used in people who are known not to tolerate erythromycin, as it has fewer gastrointestinal adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Finch et al, 2010</a>].</li></ul></li><li>Review is recommended every few days depending on the severity of symptoms to monitor the effectiveness of therapy. There is no consensus in the literature in relation to the duration of antibiotic administration and expert opinion varies  in the range of 1 to 4 weeks depending on individual response [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>]. <ul><li>The recommendation on duration of initial empirical antibacterial therapy is also based on a document from the Commission on Human Medicines (formerly the Committee on Safety of Medicines) which states that cholestatic jaundice and hepatitis may occur with administration of flucloxacillin, particularly if the person is treated for more than 2 weeks and is elderly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">CSM, 2004</a>].</li><li>Expert opinion suggests that people with prolonged symptoms or an immunocompromised state may require a longer course of antibiotic treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Wasserman et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>], and therefore CKS recommends seeking specialist advice in this scenario. </li><li>The decision to admit or refer depends on any comorbidities, the severity of symptoms and if the person is systemically unwell, in which case intravenous antibacterial therapy may be recommended in secondary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Cassidy and Shubert, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>]. </li></ul></li><li>Intra-bursal injection of antibiotics is not recommended as it has not shown any advantage over oral or intravenous treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">McFarland et al, 2000</a>].</li></ul><h5>Repeated aspiration for septic bursitis</h5><ul><li>Some experts in review articles on the management of olecranon bursitis suggest that antibiotic treatment alone is not enough in most cases of septic olecranon bursitis and recommend aspirating repeatedly if necessary, as fluid accumulates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Shell et al, 1995</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Stell, 1996</a>]. Repeated aspiration may benefit people with re-accumulation of fluid, tenderness, and continued infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">McFarland et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>].</li><li>However, other experts highlight the controversy surrounding repeated needle aspirations of the infected bursa. It is acknowledged that needle drainage is minimally invasive and may reduce the need for open drainage of the infected bursa, but drainage may be inadequate and there is a risk of creating a chronically-draining sinus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Wasserman et al, 2009</a>].</li><li>There is no consensus from expert opinion regarding repeated aspiration and therefore CKS recommends considering repeated aspiration, but only if there is expertise and experience with this procedure.  </li></ul><h5>Treatment of underlying conditions</h5><ul><li>Expert opinion in a chapter from a textbook on olecranon bursitis and a review article suggests that crystal-induced bursitis usually responds to treatment for gout with nonsteroidal anti-inflammatory drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Cassidy and Shubert, 2014</a>]</li><li>The recommendation to treat cellulitis is based on expert opinion that empiric antibiotic treatment should be started if cellulitis is present [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">McFarland et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Cassidy and Shubert, 2014</a>].</li></ul><!-- end field 9a932cb9-1ea7-4fb4-b6f0-54a9b2a0a101 --><!-- end item dd5fd99e-79ac-4ae0-be1b-6eca34c9078c -->","subChapters":[]}]},{"id":"ee4378e0-1d86-5f66-bdf4-41cdd5ba07b1","slug":"admission-or-referral","fullItemName":"Admission or referral","depth":3,"htmlHeader":"<!-- begin field fa60a91f-ba6c-4821-89fe-046742c5d661 --><h3>When should I admit or refer a person with olecranon bursitis?</h3><!-- end field fa60a91f-ba6c-4821-89fe-046742c5d661 -->","summary":null,"htmlStringContent":"<!-- begin item 0f6e08f5-7a4f-4412-b324-082a3638f5b4 --><!-- begin field b41a2eaa-cb88-4e43-a306-4c74bb323873 --><ul><li>Admit the person urgently if they have:<ul><li>A suspected septic joint (which presents with a limited range of movement of the elbow joint, unlike septic bursitis).</li><li>Septic bursitis and severe infection or systemic toxicity, including high fever.</li></ul></li><li>Admit the person on the same day if they have:<ul><li>Septic bursitis and <ul><li>Extensive cellulitis.</li><li>A pointing abscess requiring incision and drainage, if the expertise to perform this procedure is not available in primary care.</li></ul></li></ul></li><li>Admission to hospital may also be required if the person is immunocompromised or has other comorbid medical conditions, such as diabetes or rheumatoid arthritis.</li><li>Refer urgently or seek specialist advice if there is no response, or an inadequate response, to an antibiotic in septic bursitis — a change in antibiotic, intravenous antibiotic, or incision and drainage may be required.</li><li>Refer if aspiration is needed but there is no expertise available in primary care.</li><li>Refer if the person experiences recurrent septic bursitis — surgical excision of the bursa may be required, but only after infection has cleared.</li><li>Consider referral if a person with non-septic bursitis, in whom septic bursitis has been excluded, does not respond after 2 months of conservative measures (refer sooner if their symptoms are pronounced, for example significant discomfort) — corticosteroid injection into the bursa or surgical management may be beneficial.</li></ul><!-- end field b41a2eaa-cb88-4e43-a306-4c74bb323873 --><!-- end item 0f6e08f5-7a4f-4412-b324-082a3638f5b4 -->","subChapters":[{"id":"3e47095e-0069-58de-8fd4-bbfe0309e575","slug":"basis-for-recommendation-361","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e361869d-c442-474b-b868-04139a468ff3 --><h4>Basis for recommendation</h4><!-- end field e361869d-c442-474b-b868-04139a468ff3 -->","summary":null,"htmlStringContent":"<!-- begin item 361549ed-1be4-475c-a05c-0b1877bab182 --><!-- begin field c4179c5d-dcb2-4665-890e-135632f477d4 --><p>The recommendations on when to admit or refer are based on expert opinion in a consensus guideline on elbow disorders from the American College of Occupational and Environmental Medicines (ACOEM) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Hegmann, 2013</a>], expert opinion in a chapter from a textbook on olecranon bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Cassidy and Shubert, 2014</a>], and expert opinion in review articles on the management of olecranon bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Reilly and Kamineni, 2016</a>], and the British Medical Journal (BMJ) Best practice review on bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>].</p><h5>Referral of people with septic bursitis</h5><ul><li>These recommendations are based on expert opinion from review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">McFarland et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>].</li></ul><h5>Referral of people with non-septic bursitis</h5><ul><li>Expert opinion suggests that surgical management may be needed if conservative measures fail [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Reilly and Kamineni, 2016</a>], therefore CKS recommends referral in this situation.</li><li>Expert opinion in a review article suggests that people with a history of bursitis lasting 2 months or longer do not improve with conservative treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Shell et al, 1995</a>]. CKS therefore recommends referral of this group for consideration of further treatment, such as corticosteroid injection.</li><li>Previous expert reviewers of this CKS topic emphasized the importance of excluding septic bursitis. They advised that if there are symptoms suggestive of septic bursitis, referral should be made sooner than the 2 month timescale.</li></ul><h5>Secondary care investigation and treatment</h5><ul><li>Investigations that may be requested in secondary care include magnetic resonance imaging to exclude osteomyelitis if response to antibiotics has been poor [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>].</li><li>Treatments potentially available in secondary care include:<ul><li>Intravenous antibiotics — may be needed if there is severe bursitis, with systemic toxicity, cellulitis, or lymphangitis, or the person is immunocompromised [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">McFarland et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Cassidy and Shubert, 2014</a>].</li><li>Open surgical drainage (rarely required, and may increase the healing time [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>].</li><li>Placement of an intra-bursal catheter to aid drainage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Stell, 1996</a>].</li><li>Bursectomy — should only be done after the infection is under control [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">McFarland et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>].</li></ul></li></ul><!-- end field c4179c5d-dcb2-4665-890e-135632f477d4 --><!-- end item 361549ed-1be4-475c-a05c-0b1877bab182 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}